false
0001534525
0001534525
2024-08-14
2024-08-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM 8-K
________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): August 14, 2024
________________________
Xenetic Biosciences,
Inc.
(Exact name of registrant as specified in charter)
Nevada |
|
001-37937 |
|
45-2952962 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
945
Concord Street |
|
Framingham, Massachusetts |
01701 |
(Address of principal executive offices) |
(Zip Code) |
(781) 778-7720
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the
Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
☐ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $0.001 par value per share |
|
XBIO |
|
The
Nasdaq Stock Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. |
Results of Operations and Financial Condition. |
On August 14, 2024, Xenetic Biosciences, Inc.
(the “Company”) issued a press release announcing results for the three months ended June 30, 2024 and providing a business
update.
The full text of the press release is furnished
as Exhibit 99.1 to this Current Report on Form 8-K and hereby incorporated in this Item 2.02 by reference. The information in this Item
2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended,
except as shall be expressly set forth by specific reference in such filing.
FORWARD-LOOKING STATEMENTS
This Form 8-K, including the press release, contains
forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. All statements contained in this Form 8-K, including the press release, other than statements of historical facts may constitute
forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “expects,”
“plans,” “projects,” “will,” “may,” “anticipates,” “believes,”
“should,” “intends,” “estimates,” and other words of similar meaning. Any forward-looking statements
contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Many factors could cause our
actual activities, performance, achievements or results to differ materially from the activities and results anticipated in forward-looking
statements. These risks and uncertainties include those described in the “Risk Factors” section as detailed from time to time
in the Company’s reports filed with the Securities and Exchange Commission (“SEC”), including the Company’s annual
report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. In addition,
forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including
potential adverse effects of public health issues, such as the COVID-19 outbreak and, geopolitical events, such as the Russian invasion
of Ukraine and conflict in the Middle East, on economic activity, competitive product development, product availability, federal and state
regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent
positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this Form 8-K, including
the press release, speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking
statements, except as required by law.
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
XENETIC BIOSCIENCES, INC. |
|
|
|
By: /s/ James Parslow |
Date: August 14, 2024 |
Name: James Parslow |
|
Title: Interim Chief Executive Officer & Chief Financial Officer |
Exhibit 99.1
Xenetic Biosciences,
Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
| – | Ongoing preclinical studies with data expected before year end |
| – | Focus on demonstration of DNase-based oncology program in clinical proof-of-concept
studies in multiple indications |
| – | Ended the quarter with $7.3 million of cash to fund operations
|
FRAMINGHAM,
MA – (August 14, 2024) – Xenetic Biosciences, Inc. (NASDAQ: XBIO) (“Xenetic”
or the “Company”), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard
to treat cancers, today reported its financial results for the second quarter of 2024.
"We remain confident in the potential
of our DNase-based oncology platform and continue to advance our preclinical studies with data expected before year end. Looking
ahead, we are focusing our resources on driving our pipeline towards first-in-human clinical studies and establishing
proof-of-concept in multiple indications. Our goal remains unwavering and we are committed to bringing a much-needed, innovative
immune-oncology treatment to patients and generating shareholder value in the near and long term," commented, James
Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic.
Xenetic is executing on its plans to advance its
DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced
or metastatic solid tumors.
Summary of Financial Results for Second Quarter
2024
Net loss for the quarter ended June 30, 2024 was
approximately $1.3 million. Research & development expenses for the three months ended June 30, 2024 of approximately $0.9 million
were relatively flat with the comparable quarter in 2023 as increases in personnel costs due to severance and benefits incurred in connection
with a separation agreement entered into during the second quarter of 2024 were substantially offset by decreases in spending in connection
with our pre-clinical and process development efforts related to our DNase platform. General and administrative expenses for the three
months ended June 30, 2024 increased by approximately $0.2 million, or 19.5%, to approximately $1.1 million from approximately $0.9 million
in the comparable quarter in 2023. The increase was primarily due to certain severance and benefits expensed in connection with a separation
agreement entered into during the second quarter of 2024 partially offset by decreases in accounting and legal fees.
Additionally, the Company reported royalty payments
of approximately $0.7 million related to its sublicense of the PolyXen® platform technology with Takeda in the quarter ended June
30, 2024, representing an approximate 11.6% increase over the quarter ended June 30, 2023.
The Company ended the quarter with approximately
$7.3 million of cash.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical
company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is
designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which
are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive
therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements
that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained
in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal
securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will,"
"may," "anticipates," "believes," "should," "intends," "estimates," "remain,"
"focus", “confidence in”, “potential”, and other words of similar meaning, including, but not limited
to, all statements regarding expectations for our DNase-base oncology platform, including statements regarding: ongoing pre-clinical studies
with data expected before year end; focusing on demonstration of DNase-based oncology program in clinical proof-of-concept studies in
multiple indications, the potential of our DNase-based oncology platform, focusing our resources on driving our pipeline towards first-in-human
clinical studies and establishing proof-of-concept in multiple indications, our commitment to bringing a much-needed, innovative
immune-oncology treatment to patients and generate shareholder value in the near and long term, and plans to advance our DNase-based oncology
program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid
tumors, our focus on advancing innovative immune-oncology technologies addressing hard to treat cancers, the DNase platform improving
outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in
cancer progression, and our focus on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma
and locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and
are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results
to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual
activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others,
(1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges
or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following
the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability
of the Company to obtain funding and implement its business strategy; and (6) other risk factors as detailed from time to time in the
Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports
on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking
statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse
effects of public health issues, such as the COVID-19 outbreak, and geopolitical events, such as the Russian invasion of Ukraine and conflict
in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation,
the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation,
and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date
the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by
law.
Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
xbio@jtcir.com
v3.24.2.u1
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Xenetic Biosciences (NASDAQ:XBIO)
Historical Stock Chart
From Oct 2024 to Nov 2024
Xenetic Biosciences (NASDAQ:XBIO)
Historical Stock Chart
From Nov 2023 to Nov 2024